Country: Kanada
Tungumál: enska
Heimild: Health Canada
CLIOQUINOL; FLUMETHASONE PIVALATE
PALADIN LABS INC.
D07CB05
FLUMETASONE AND ANTIBIOTICS
3%; 0.02%
CREAM
CLIOQUINOL 3%; FLUMETHASONE PIVALATE 0.02%
TOPICAL
50G
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0204579001; AHFS:
APPROVED
2006-03-01
PRESCRIBING INFORMATION PR LOCACORTEN ® VIOFORM ® (FLUMETHASONE PIVALATE 0.02% - CLIOQUINOL 3%) CREAM Topical Corticosteroid with Antibacterial - Antifungal Agent Paladin Labs Inc. Date of Preparation: 6111 Royalmount Ave., suite 102 June 9, 2009 Montréal, Québec H4P 2T4 Control # 130473 Pr LOCACORTEN ® and VIOFORM ® are registered trademarks of Novartis Pharmaceuticals Canada Inc. - 2 - PRESCRIBING INFORMATION PR LOCACORTEN ® VIOFORM ® (flumethasone pivalate 0.02% - clioquinol 3%) Cream Topical Corticosteroid with Antibacterial-Antifungal Agent ACTIONS AND CLINICAL PHARMACOLOGY LOCACORTEN (flumethasone pivalate) is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a pivalate, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching. VIOFORM (clioquinol), the antimicrobial component of LOCACORTEN VIOFORM (flumethasone pivalate/clioquinol), is active against a broad spectrum of pathogenic microorganisms, including fungi (e.g., Candida, Microsporum, Trichophyton) and gram-positive bacteria (e.g., Staphylococci). Clioquinol has only a slight inhibitory effect on gram-negative bacteria. Clioquinol exerts a bacteriostatic, rather than a bactericidal action. LOCACORTEN VIOFORM combines the antifungal and antibacterial effects of clioquinol with the anti-inflammatory and antipruritic effects of flumethasone. INDICATIONS AND CLINICAL USE LOCACORTEN VIOFORM (flumethasone pivalate/clioquinol) is indicated in the initial treatment of corticosteroid-responsive inflammatory skin disorders complicated by bacterial and/or fungal infections, with appropriate systemic antibiotics if necessary, such as: seborrheic dermatitis, atopic dermatitis, localized neurodermatitis, contact dermatitis, intertrigo, superficial forms of pyoderma (e.g., impetigo) and of dermatomycosis in which acute inflammation is a prominent feature. T Lestu allt skjalið